HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Bronchiectasis — Clinical Guidelines

Overview

Bronchiectasis is a chronic lung condition characterized by irreversible dilation and thickening of bronchial walls, often leading to recurrent infections, exacerbations, and significant morbidity. It encompasses a wide range of underlying causes including infectious, immunological, and genetic factors 1 5.

Diagnosis

Clinical Presentation: Persistent cough, sputum production, recurrent respiratory infections 1.

Imaging: High-resolution computed tomography (HRCT) is essential for confirming bronchiectasis and assessing severity 1 8.

Laboratory Tests: Sputum cultures to identify pathogens; blood tests to rule out underlying conditions 1.

Grading: Use validated scoring tools like the Bronchiectasis Severity Index (BSI) to assess disease severity and predict outcomes 8.

Management

First-Line Treatments:

- Airway Clearance Techniques: Including physiotherapy to enhance mucus clearance 15 18. - Antibiotics: For acute exacerbations; long-term macrolides (e.g., azithromycin) to reduce frequency of exacerbations in stable patients 14 12.

Adjunctive Treatments:

- Exercise Training: To improve physical fitness and quality of life 12. - Management of Underlying Causes: Investigate and treat any identifiable causes such as autoimmune diseases or immunodeficiencies 1.

Special Populations

Pregnancy: Bronchiectasis patients generally tolerate pregnancy well; maternal hypoxemia may cause intrauterine growth retardation 24 25.

Pediatrics: Increasing recognition; management focuses on improving clinical outcomes and quality of life 7.

Elderly: Preoperative respiratory optimization (e.g., respiratory prehabilitation) is crucial for surgical interventions 3.

Comorbidities: Polypharmacy and complex medication regimens may influence antibiotic use; careful management is advised 11.

Key Recommendations

Investigate and treat underlying causes to improve long-term outcomes (Evidence: Strong 1).

Utilize validated scoring tools like the Bronchiectasis Severity Index (BSI) to assess disease severity and guide management (Evidence: Moderate 8).

Implement long-term macrolide therapy (e.g., azithromycin) for stable adult patients to reduce exacerbation frequency (Evidence: Moderate 14).

Incorporate airway clearance techniques such as chest physiotherapy to enhance mucus clearance (Evidence: Weak 18).

Regular monitoring and management of exacerbations with appropriate antibiotic therapy are essential (Evidence: Moderate 12).

References

1 Chalmers JD, Haworth CS, Flume P, Long MB, Burgel PR, Dimakou K et al.. European Respiratory Society clinical practice guideline for the management of adult bronchiectasis. The European respiratory journal 2025. link 2 Chatziparasidis G, Kantar A, Rafailia Chatziparasidi M, Fouzas S, Bush A, Chang A. The potential effects of climate change on non-cystic fibrosis bronchiectasis in children. Paediatric respiratory reviews 2025. link 3 Takahashi T, Yoshida M, Ito N, Koizumi K, Kamio H, Oda A et al.. Anesthetic Management for an Elderly Patient With Severe Bronchiectasis. Anesthesia progress 2025. link 4 Fujii H, Hara Y, Obase Y, Haranaga S, Takahashi H, Shinkai M et al.. Nationwide survey in Japan of the causative diseases of bloody sputum and hemoptysis in departments of respiratory medicine at university hospitals and core hospitals. Respiratory investigation 2024. link 5 Chalmers JD. Bronchiectasis from 2012 to 2022. Clinics in chest medicine 2022. link 6 Olmedo DWV, Martins KB, Paz MM, Fernandes CLF, Silva Júnior FMRD, Ramos DF. Mutagenic damage among bronchiectasis patients attending in the pulmonology sector of a hospital in southern Brazil. Revista da Associacao Medica Brasileira (1992) 2022. link 7 Chang AB, Fortescue R, Grimwood K, Alexopoulou E, Bell L, Boyd J et al.. European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis. The European respiratory journal 2021. link 8 Young SL, Puan Y, Chew SY, Haja Mohideen SM, Tiew PY, Tan GL et al.. Heterogeneity of non-cystic-fibrosis bronchiectasis in multiethnic Singapore: A prospective cohort study at a tertiary pulmonology centre. Annals of the Academy of Medicine, Singapore 2021. link 9 Melnikova N, Wu J, Ruiz P, Orr MF. National Toxic Substances Incidents Program - Nine States, 2010-2014. Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002) 2020. link 10 Schoovaerts K, Lorent N, Goeminne P, Aliberti S, Dupont L. National Survey on the Management of Adult Bronchiectasis in Belgium. COPD 2019. link 11 Spargo M, Ryan C, Downey D, Hughes C. The association between polypharmacy and medication regimen complexity and antibiotic use in bronchiectasis. International journal of clinical pharmacy 2018. link 12 Smith MP. Diagnosis and management of bronchiectasis. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2017. link 13 Hill AT, Haworth CS, Aliberti S, Barker A, Blasi F, Boersma W et al.. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. The European respiratory journal 2017. link 14 Hill AT. Macrolides for Clinically Significant Bronchiectasis in Adults: Who Should Receive This Treatment?. Chest 2016. link 15 Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. The European respiratory journal 2015. link 16 Martínez-García MÁ, de Gracia J, Vendrell Relat M, Girón RM, Máiz Carro L, de la Rosa Carrillo D et al.. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. The European respiratory journal 2014. link 17 De Soyza A, Brown JS, Loebinger MR. Research priorities in bronchiectasis. Thorax 2013. link 18 Murray MP, Pentland JL, Hill AT. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. The European respiratory journal 2009. link 19 Peres A. Nursing patients with bronchiectasis: part one. Nursing times 2008. link 20 Jones VF, Eid NS, Franco SM, Badgett JT, Buchino JJ. Familial congenital bronchiectasis: Williams-Campbell syndrome. Pediatric pulmonology 1993. link 21 Kaneko K, Kudo S, Tashiro M, Kishikawa T, Nakanishi Y, Yamada H. Case report: computed tomography findings in Williams-Campbell syndrome. Journal of thoracic imaging 1991. link 22 Akoojee SB, Whitton I. Endobronchial lipoma. A case report. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 1979. link 23 Butler H, Lake KB, Van Dyke JJ. Bronchial endometriosis and bronchiectasis. A possible relationship. Archives of internal medicine 1978. link 24 Howie AD, Milne JA. Pregnancy in patients with bronchiectasis. British journal of obstetrics and gynaecology 1978. link 25 Templeton A. Intrauterine growth retardation associated with hypoxia due to bronchiectasis. British journal of obstetrics and gynaecology 1977. link

Bronchiectasis